View Older Stories
-
China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck
-
Sanofi expands AI center in Toronto with $294 million investment
-
Morgan Stanley Downgrades Sanofi (SNY) to Equalweight
-
Sanofi climbs as strong Dupixent sales drive Q1 revenue and profit beat
-
Sanofi (SNY) Tops Q1 EPS by 9c
-
FDA approves Sanofi's Tzield for children as young as one year old
-
Goldman Sachs sees nearly 140% upside in this biopharma stock
-
BNP Paribas Exane Downgrades Sanofi (SNY) to Neutral
-
Sanofi (SNY) PT Lowered to $55 at Morgan Stanley
-
US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
-
DNDi and Sanofi drug receives CHMP positive opinion for sleeping sickness
-
Sanofi cut to "neutral" at BofA on CEO change, shares drop over 6%
-
BofA Securities Downgrades Sanofi (SNY) to Neutral, 'CEO change brings another transition. Limited catalysts'
-
BofA Securities Downgrades Sanofi (SAN:FP) (SNY) to Neutral
-
Should you own Sanofi stock in 2026? Citi answers
-
Sanofi (SNY) Tops Q4 EPS by 69c; offers outlook
-
Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'
-
UBS Downgrades Sanofi (SAN:FP) (SNY) to Neutral
-
FDA delays reviews of Sanofi's Tzield and Disc Medicine's bitopertin
-
Sanofi (SNY) CEO: expect to maintain double digit growth for next half decade - JPM Conference
-
Sanofi (SNY) January 50 calls active into the annual J.P. Morgan Healthcare Conference
-
FDA approves Cablivi for rare blood disorder in kids
-
FDA approves Sanofi's Cablivi for pediatric blood clotting disorder
-
Drugmakers Raise Us Prices On 350 Medicines Despite Pressure From Trump - Reuters
-
TD Cowen Reiterates Hold Rating on Sanofi (SNY)
-
TD Cowen Reiterates Hold Rating on Sanofi (SAN:FP) (SNY)
-
BTIG on Apogee (APGE): 'DUPLEX-AD's Failure is Likely a Clearing Event for APG279 and APG777 in Atopic Dermatitis'
-
Jefferies Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Jefferies Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Sanofi wins EU approval for Wayrilz to treat immune thrombocytopenia
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
Sanofi reaches deal with US government to cut drug prices
-
At Least 7 Drug Companies to Announce Price Cuts with Trump at White House - WaPo
-
Dren Bio secures $100 million from Sanofi for B-cell therapy collaboration
-
Guggenheim Downgrades Sanofi (SNY) to Neutral
-
Guggenheim Downgrades Sanofi (SAN:FP) (SNY) to Neutral
-
Valuation in this big pharma stock continues to be attractive: analyst
-
Increasing unusual put option volume: BAX SNY XP GPN AVXL CAPR EXE WY HROW VG
-
Novavax completes US marketing transfer to Sanofi, receives $25 million
-
Sanofi (SNY) Tops Q3 EPS by 72c
-
Sanofi earnings preview: Stable quarter expected
-
Sanofi’s third-quarter results seen steady as margin outlook draws focus
-
Sanofi high-dose flu vaccine cuts hospitalizations 32% in older adults
-
Revvity partners with Sanofi to develop type 1 diabetes screening test
-
Novavax expands Sanofi license for Matrix-M adjuvant use
-
M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
-
Berenberg Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
-
Sanofi expands insulin program to $35 monthly cap for all US patients
-
FDA removes safety restrictions for Sanofi thyroid cancer drug
-
Sanofi (SNY) ordered to pay EUR 150.7M in France over anti-competitive behaviour

